FindTrial
Sign In

Clinical trial of transcatheter arterial chemoembolization combined with lanreotide and celecoxib in the treatment for hepatocellular carcinoma

Clinical trial of transcathether arterial chemoembolization (TACE) combined with non-cytotoxic drugs in hepatocellular carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-08000191
Enrollment
Unknown
Registered
2008-10-20
Start date
2008-10-21
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

TACE:Receive TACE
TACE+C:Receive TACE and celecoxib
TACE+C+L:Receive TACE and celecoxib

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years; 2. CLIP score 2 - 5 and BCLC stage B - C; 3. Treatment-naive.

Exclusion criteria

Exclusion criteria: 1. End-stage liver disease (Child-Pugh grade C); 2. Active gastrointestinal bleeding; 3. Hepatic encephalopathy; 4. Refractory ascites; 5. Extrahepatic metastasis; 6. Severe portosystemic shunt and hepatofugal blood flow; 7. Impaired clotting tests (platelet count < 50*10^9/L or prothrombin activity < 50%); 8. Renal dysfunction; 9. Other severe systemic diseases; 10. Pregnant or breeding women; 11. Hyperallergic to drugs involved in this study or sulfanilamide.

Design outcomes

Primary

MeasureTime frame
Survival time and survival rate;Tumor respons;—

Secondary

MeasureTime frame
Quality of life, etc.;—

Countries

China

Contacts

Public ContactChengwei Tang
shcqcdmed@163.com+86 28 18980601275

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026